Skip to main content
Clinical Trials/NCT05751772
NCT05751772
Terminated
N/A

Disease and Medication Knowledge Improvement: A Swiss Single-center Randomized Controlled Trial With Heart Failure Inpatients

University Hospital, Geneva1 site in 1 country38 target enrollmentDecember 13, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure With Reduced Ejection Fraction
Sponsor
University Hospital, Geneva
Enrollment
38
Locations
1
Primary Endpoint
Change in knowledge score
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients. The knowledge score on heart failure disease and medications will be compared between two groups one month after hospitalization. The intervention group will receive a therapeutic education intervention and usual hospital care and the control group will receive only usual hospital care.

Detailed Description

Heart failure patients are at risk of decompensation of their disease and frequent hospitalizations. Poor adherence to their treatment may be the cause. By improving the knowledge of hospitalized heart failure patients about their disease and their medications, it is expected that these patients will adhere better to their heart failure drug therapy and benefit from a better effectiveness of their treatment. This could promote an improvement in their quality of life, a decrease in their risk of disease complications and even an increase in their life expectancy. The objective of this research project is to deploy a therapeutic teaching intervention at the bedside of decompensated and hospitalized heart failure patients, associated with follow-up by the pharmacist at discharge from the hospital, and to measure its impact on knowledge change (primary endpoint), on their beliefs about medications, on their therapeutic adherence, and on the consumption of unplanned care such as rehospitalizations and emergency room visits (secondary endpoints).

Registry
clinicaltrials.gov
Start Date
December 13, 2022
End Date
January 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mégane Jermini

Hospital and Clinical Pharmacist, pharmD, Principal Investigator

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • Hospitalization in the Department of General Internal Medicine or Cardiology for decompensated heart failure with lowered left ventricular ejection fraction (LVEF) (≤40%) from any cause or mildly lowered LVEF (41-49%) with the presence of heart failure-specific drug therapy
  • Stability of the patient's clinical condition
  • ≥ 2 heart failure medications
  • ≥18 years
  • Full capacity of discernment
  • Absence of cognitive impairment
  • Ability to speak, understand and read in French
  • Get a personal telephone
  • Consent form signed by the participant

Exclusion Criteria

  • Inability to follow study procedures
  • Institutionalized persons
  • Asylum seekers, homeless people, prisoners
  • Incapacity of judgment and discernment

Outcomes

Primary Outcomes

Change in knowledge score

Time Frame: at the baseline time (zero time), immediately after therapeutic education intervention and 30 days after hospital discharge

Patients' level of knowledge about their disease and heart failure medications before the educational pharmaceutical intervention (pre-test) and immediately after the intervention (post-test n° 1) for the intervention group , as well as at 1 month after hospital discharge (post-test n°2) for the intervention and control group. It will be measured by means of a 17-question questionnaire specifically developed for this project. This level is valued by a minimum score of 0 points and a maximum of 17 points. Higher score means a better level of knowledge. The positive difference between pre-test and post-tes means an increase in knowledge and a negative difference means a decrease in knowledge.

Secondary Outcomes

  • Change in Beliefs about medicines Score(at the baseline time (zero time),30 days after hospital discharge)
  • Change in Medication Adherence Score(at the baseline time (zero time),30 days after hospital discharge)
  • Level of satisfaction on therapeutic education(immediately after therapeutic education intervention)
  • Patient experiment and feeling after discharge(7 days after hospital discharge)
  • Level of satisfaction on global pharmaceutical care(30 days after hospital discharge)
  • Rehospitalization or emergency room visits(30 days after hospital discharge)
  • Self-Care of Heart Failure Index(30 days after hospital discharge)
  • Death at 1 month after discharge(30 days after hospital discharge)
  • CardioMeds app usability(30 days after hospital discharge)

Study Sites (1)

Loading locations...

Similar Trials